PT-141 dosage and evidence

What is PT-141?

How does PT-141 work?

It switches on melanocortin receptors in the brain, mostly one called MC4R. Those are part of the brain's desire and arousal pathways.

What have studies in people found about PT-141?

Bremelanotide (PT-141) has a well-recorded safety record: 3,500 people across 43 finished studies. Two large final-stage trials in 1,267 women before menopause led to its US approval. How much it really helps, and whether the questionnaires used to measure that were sound, is disputed in medical journals.

• Safety across all studies: 3,500 people in 43 finished studies, some taking it for up to 18 months. In the 1,247 people in the large final-stage trials, 40.0% felt sick on the drug against 1.3% on a dummy shot. Flushing hit 20.3% against 1.3%, headache 11.3% against 1.9%, and shot-site reactions 5.4% against 0.5%. Feeling sick was the most common reason people quit. Dark patches on the skin were rare at the label dose. But they showed up in more than a third of people given up to 16 daily doses in a row. 70% of the drug group went on to the next phase, against 87% of the dummy group.
• The two approval trials: 1,267 women before menopause with low sexual desire that caused them distress (a diagnosis called hypoactive sexual desire disorder), over 24 weeks. Taking 1.75 mg when needed raised desire scores by 0.35 points on a questionnaire and eased distress about low desire, compared with a dummy shot. Nausea, flushing and headache each hit 10% or more.
• Long-term follow-on: 684 women went on into a 52-week stretch where everyone got the drug. That gave the long-term safety data behind the approval.
• Blood pressure: 397 women before menopause, with normal or controlled blood pressure, wore round-the-clock monitors across three doses. At 1.75 mg the top blood pressure number rose 3.1 to 3.2 points more than on a dummy shot in the first 4 hours. The peaks usually lasted under 15 minutes. Heart rate fell 4.6 to 4.7 beats a minute. 26 women stopped because of blood pressure rises, at similar rates in all four groups, dummy included.
• An independent check in 2024: an academic team compared the approval trials with what they had promised to report on the public registry. 8 of the 11 benefit measures listed there had never been published, including total scores on the two main questionnaires. When the team analysed them, the benefits ranged from nothing to small. They also say the evidence that the desire and distress questionnaires work in these women is shaky at best.
• An earlier dose study worked out the smallest change a woman would notice on seven questionnaire measures. At 1.75 mg, all seven favoured the drug over the dummy by more than chance. Those same yardsticks were then used in the approval trials.

What this does not tell you: All the evidence of benefit is in women before menopause with a diagnosis of lasting low sexual desire. No published trial supports its use in men, for erection problems, or in women after menopause. Those are big parts of the off-label market. The blood pressure rise is small on average. But it was measured in women checked to have normal or controlled blood pressure, so it says nothing about someone with untreated high blood pressure. Dark skin patches depend on how often it is taken, and the daily-dose data show how fast they appear. That matters for people using drugs like this for tanning. The size of the benefit is the disputed part. The trials hit the targets they set in advance. An independent group looking at every measure the trials registered says the benefits are modest, on questionnaires that may not measure what they claim.

What do people who took PT-141 report?

This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.

• Nausea dominates the discussion and is described as the main reason people stop. Accounts range from a couple of hours of it to being unable to leave a bathroom for the better part of a day. This is the clearest negative of any compound in this set.
• Several people describe taking an anti-nausea prescription an hour beforehand on a doctor's advice and reporting that it made the difference between abandoning it and continuing.
• The strategy most repeated by experienced users is starting at a much lower dose than the label amount and working up, specifically to stay under the nausea threshold. Threads devoted to low-dose approaches are among the most read on the topic.
• Effects on erection and desire are described as strong when they land, with people comparing them favourably to injectable alternatives, but timing is reported as unpredictable, commonly taking around 45 minutes and sometimes far longer.
• Duration is described as long, with some reporting effects persisting around a day, and spontaneous erections afterwards are raised both as a benefit and as a nuisance.
• Flushing and headache come up regularly alongside nausea, and the overall picture people describe is a compound that works but is difficult to tolerate at conventional doses.

Sources: Threads on ExcelMale, Bluelight and LongeCity, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.

The state of the research

The evidence, in charts

The studies we cite

• Study in people2019
  Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT)

  It raised sexual desire in women by a small but real amount, and made a lot of them feel sick. 1,267 premenopausal women with low sexual desire used bremelanotide as needed, or a dummy injection, over about six months across two matching trials. Desire scores rose and distress about low desire fell, more than on the dummy. The gain was modest, about a third of a point on the desire scale. Nausea, flushing and headache each hit at least one woman in ten.

  1,267 premenopausal women across two identical 24-week trials: bremelanotide 1.75 mg as needed significantly increased FSFI desire scores (+0.35 integrated) and reduced desire-related distress versus placebo; nausea, flushing and headache in 10% or more.

  PMID 31599840 Obstetrics & Gynecology
• Study in people2019
  Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder

  This is where the safety record for long-term use comes from, and everybody in it was on the drug. 684 women carried on with bremelanotide for a further year after the main trials ended. Nobody received a dummy injection at this stage. That makes it useful for spotting side effects that take time to appear, and useless for telling whether the drug still helps. Women who could not tolerate it had already dropped out earlier, so what is left is the group it suited.

  684 women entered the 52-week open-label extension of RECONNECT, providing the long-term safety data behind the approval.

  PMID 31599847 Obstetrics & Gynecology
• Study in people2017
  Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide

  Bremelanotide raises blood pressure a little and slows the heart, for a short while after each shot. 397 premenopausal women wore blood pressure monitors around the clock. At the label dose the top blood pressure number ran about 3 mmHg higher than on the dummy in the four hours after the shot, with peaks usually lasting under 15 minutes. Heart rate fell about 4.6 beats per minute. 26 women stopped for blood pressure rises, about equally in every group, dummy included.

  397 premenopausal women: ambulatory systolic pressure rose 3.1 to 3.2 mmHg versus placebo at 1.75 mg in the first four hours, with peaks usually under 15 minutes, and heart rate fell 4.6 to 4.7 beats per minute. 26 participants discontinued for prespecified blood pressure rises, similarly across all groups.

  PMID 27977473 Journal of Hypertension
• Study in people2019
  Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide

  This study decided what counts as a meaningful improvement, before the big trials measured it. Researchers worked out the smallest change on seven patient-reported measures that a woman would actually notice. At the 1.75 mg dose all seven favoured bremelanotide over the dummy by more than chance explains. Those same definitions were then carried into the two large RECONNECT trials. Setting the yardstick and then using it is normal practice, and it is also worth knowing who set it.

  Derived minimal clinically important differences for seven patient-reported endpoints; at 1.75 mg all seven reached significance versus placebo (P at most .03). These responder definitions were then carried into the RECONNECT Phase 3 trials.

  PMID 31277966 Journal of Sexual Medicine
• Review of studies2019
  Vyleesi (bremelanotide injection) NDA 210557 approval letter

  The FDA's approval letter. On June 21, 2019, the FDA approved bremelanotide for women who have not gone through menopause and have lost their sexual desire over time.

  FDA approval (June 21, 2019) of bremelanotide for premenopausal women with acquired, generalized hypoactive sexual desire disorder.

  Source U.S. Food and Drug Administration
• Review of studies2022
  Safety Profile of Bremelanotide Across the Clinical Development Program

  The side effects are common, well documented and mostly unpleasant rather than dangerous. Data were pulled together from 3,500 people across 43 completed studies. Among the 1,247 in the late-stage group, 40.0% felt sick against 1.3% on the dummy, 20.3% flushed against 1.3%, and 11.3% got headaches against 1.9%. Feeling sick was the commonest reason people quit. Patches of darkened skin were rare at label dosing but appeared in over a third of people given up to 16 daily doses in a row.

  3,500 subjects across 43 completed studies: in the integrated double-blind Phase 3 population of 1,247, nausea 40.0% versus 1.3%, flushing 20.3% versus 1.3% and headache 11.3% versus 1.9%. Focal hyperpigmentation occurred in more than a third of subjects given up to 16 consecutive daily doses.

  PMID 35147466 Journal of Women's Health
• Review of studies2024
  Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder

  An independent team checked the approval trials against what they had promised to report, and most of it was missing. 8 of the 11 benefit measures listed on the public registry had never been published. When the team analysed those measures, the benefits ranged from nothing to small. They also argue the questionnaires used to score desire and distress have not been properly validated in these women. The sponsor's answer is that the regulator agreed the measures in advance and they were met.

  Independent audit of the RECONNECT trials against their registry entries: 8 of the 11 ClinicalTrials.gov-specified efficacy outcomes were unpublished. On analysis, effect sizes ranged from nil to small, and the authors report the desire and distress instruments have questionable validity evidence in this population.

  PMID 36809187 Journal of Sex Research